Special Guest Speaker: Kathy Meyer, Clinical Nurse Educator, Janssen Pharmaceuticals will provide an update on Darzalex which was approved by the FDA to treat multiple myeloma on November 16, 2015. DARZALEX® is not chemotherapy.
DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them.
DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells.
For more information, please visit https://www.darzalex.com/